COMP <GO>
TECH vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Bio-Techne Corp (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TECH 2
— JNJ 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TECH
LAST: $72.71 (+0.03%) • MKT CAP: $11.40B
balance-sheet
7.12
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 67.90% | -3.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 25.50% | -22.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.3x | 18.5x | +72.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 2.97% | -0.72 | JNJ | /fcf-yield <GO> |
| Operating Margin | 8.40% | 34.70% | -26.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 28.50% | -22.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 6.00% | -0.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.00% | +0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 7.12 | 5.59 | +1.53 | TECH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 62.1 | -2.80 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 23.0x | +117.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.40B | $662.49B | -$651.09B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | JNJ REV | TECH GROSS % | JNJ GROSS % | TECH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $94.19B | 64.8% | 67.9% | $256.6M | $19.70B |
| FY 2024 | $1.16B | $88.82B | 66.4% | 69.1% | $236.1M | $19.84B |
| FY 2023 | $1.14B | $85.16B | — | — | $203.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
JNJ // BETA 1.08